(Q37086026)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Current concepts in malignant pleural mesothelioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Andrew J Kaufman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

293-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

Asbestos and mesothelioma: worldwide trends

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Malignant pleural mesothelioma: current concepts in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Asbestos Disease at Low Exposures after Long Residence Times

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Wittenoom, Western Australia: a modern industrial disaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Malignant mesothelioma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Chrysotile asbestos is the main cause of pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Environmental mesothelioma in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Asbestos-associated chromosomal changes in human mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Pleural macrophage recruitment and activation in asbestos-induced pleural injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Interleukin 6 induces the expression of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

The pathogenesis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

SV40 and human tumours: myth, association or causality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

MESOMARK: a potential test for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Gene expression profiles predict survival and progression of pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

The role of PET in the surgical management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Positron emission tomography predicts survival in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

CT, RECIST, and malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Validation of genomics-based prognostic tests in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

The management of malignant pleural mesothelioma; single centre experience in 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Thalidomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

Eighth International Mesothelioma Interest Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.2.293

21 January 2018

Identifiers

DOI

10.1586/14737140.8.2.293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18279069%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference